Democrats’ drug pricing deal bars pharmacy benefit managers from entering into contracts with drug makers that limit the disclosure of information to health plan sponsors, among other reporting requirements. The text does not, however, include provisions for combating spread pricing, drug rebates or pharmacy price concessions. After initially excluding government drug price controls from their reconciliation bill, Democrats reinserted policies to let Medicare negotiate drug prices in limited circumstances and make drug companies pay back Medicare when they raise prices...